DNLI News and Press, Denali Therapeutics Inc. From 11/06/19

Denali Therapeutics (NASDAQ: DNLI ): Q3 GAAP EPS of -$0.48 beats by $0.09 . More news on: Denali Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the third quarter ended September 30, 2...

It can be hard for a non-scientist to judge the validity of a biotech's claims. Are this company's drugs going to be approved by the FDA? How valid is its research? These questions are almost impossible to answer. Even the scientists themselves can't be sure they're right until the clinical tria...

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's disease, is a progressive neurodegenerative disease in which the nerve cells in the spinal cord and brain slowly die, leading to impairment of voluntary muscle movement. Patients lose the ability to eat, breathe, walk, and talk ...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Outperform rating and $146 (45% upside) price target at William Blair. More news on: Alexion Pharmaceuticals, Inc., Change Healthcare Inc., Denali Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Drug development is a losing game full of highly trained professionals who would rather be lucky than talented at their jobs. This is because experimental new drugs fail so frequently that an entire career without one successful new drug discovery under their belts isn't uncommon. Doing everyth...

Denali Therapeutics (NASDAQ: DNLI ) initiated with Buy rating and $35 (84% upside) price target at Nomura Instinet. More news on: Denali Therapeutics Inc., Intuitive Surgical, Inc., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Pixabay Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical ...

Phase 1b study of DNL151 includes Parkinson’s disease patients with and without a genetic LRRK2 mutation Either DNL151 or DNL201 anticipated to be selected for potential registrational clinical trials in 2020 The Engage Parkinson’s website provides patients, caregivers...

Addus HomeCare (NASDAQ: ADUS ) initiated with Outperform rating at William Blair. More news on: Addus HomeCare Corporation, Denali Therapeutics Inc., Cronos Group Inc., Healthcare stocks news, Stocks on the move, , Read more ...